Released on: October 30, 2008, 4:05 am

Press Release Author: Thermo Fisher Scientific

Industry: -- Choose an Industry --

Press Release Summary: Thermo Fisher Scientific Inc., the world leader in serving
science, today announced its collaboration with the Molecular Therapeutics Research
Group at the School of Pharmacy, Queen's University Belfast to analyze peptides
within amphibian venom. The facility is using a Thermo Scientific LTQ Orbitrap XL(tm)
high performance mass spectrometer on a trial basis with the aim of expanding its
research capabilities to deliver the mass accuracy required for complex peptide
identification and the data reliability needed for the de novo sequencing of
peptides.

Press Release Body: FOR IMMEDIATE RELEASE
Chromatography and Mass Spectrometry
Media Contact Information:
Name: Laura Browne/ Sophie Downend
Phone: +44 1477 539539
Email: thermouk@scottpr.com

Secondary Contact Information:
Dr Paul Humphrey
+44 1442 233555
paul.humphrey@thermofisher.com

Thermo Fisher Scientific Announces Collaboration with Queen's University Belfast for
the Analysis of Peptides within Amphibian Venoms

HEMEL HEMPSTEAD, UK. (October 29, 2008) - Thermo Fisher Scientific Inc., the world
leader in serving science, today announced its collaboration with the Molecular
Therapeutics Research Group at the School of Pharmacy, Queen's University Belfast to
analyze peptides within amphibian venom. The facility is using a Thermo Scientific
LTQ Orbitrap XL(tm) high performance mass spectrometer on a trial basis with the aim of
expanding its research capabilities to deliver the mass accuracy required for
complex peptide identification and the data reliability needed for the de novo
sequencing of peptides.

Headed by Professor Chris Shaw, specialist in novel peptide drug discovery, the
Molecular Therapeutics Research Group is currently focusing its efforts on the
isolation, structural characterization and functional evaluation of novel peptides
extracted from amphibian, snake and arthropod venoms. Previous research in this area
by other scientists has unearthed a number of groundbreaking drug discoveries
including potential treatment for high blood pressure and possible cures for deep
vein thrombosis and heart disease. Recognizing the huge potential for drug discovery
from the analysis of natural peptides, Shaw now hopes that the research facility at
Queen's University Belfast will prove pivotal in the future of drug discovery.

Professor Chris Shaw comments: "The LTQ Orbitrap XL is a state-of-the-art instrument
in terms of advanced proteomics and small molecule analysis. The system's incredible
mass accuracy enables much easier de novo sequencing, thus lowering productivity
costs and the unit cost of identifying each peptide structure."

Shaw continues, "The revolutionary Orbitrap technology has enabled us to determine
that the synthetic replicate produced in analysis is highly accurate in terms of
molecular characterization identical to the natural compound. This means our
researchers can now be 100% confident that they have the correct molecule for the
research program. This is the first time that this has been possible using this type
of proteomics instrumentation, and it means that we can avoid the possibility of
working for years on fruitless research."

Based on the fast and highly sensitive Thermo Scientific LTQ XL(tm) linear ion trap and
the patented Orbitrap(tm) technology, the LTQ Orbitrap XL high performance mass
spectrometer supports a wide range of applications from routine compound
identification to the most challenging analysis of low level components in complex
mixtures.

Queen's University Belfast believes that these trials will mark the start of
significant advancement in this research area and enable novel peptide drug
discovery leads in the future. For more information about the Thermo Scientific LTQ
Orbitrap XL high performance mass spectrometer, please call +1 800-532-4752, e-mail
analyze@thermo.com or visit www.thermo.com/orbitrap.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science,
enabling our customers to make the world healthier, cleaner and safer. With annual
revenues of $10 billion, we have more than 30,000 employees and serve over 350,000
customers within pharmaceutical and biotech companies, hospitals and clinical
diagnostic labs, universities, research institutions and government agencies, as
well as environmental and industrial process control settings. Serving customers
through two premier brands, Thermo Scientific and Fisher Scientific, we help solve
analytical challenges from routine testing to complex research and discovery. Thermo
Scientific offers customers a complete range of high-end analytical instruments as
well as laboratory equipment, software, services, consumables and reagents to enable
integrated laboratory workflow solutions. Fisher Scientific provides a complete
portfolio of laboratory equipment, chemicals, supplies and services used in
healthcare, scientific research, safety and education. Together, we offer the most
convenient purchasing options to customers and continuously advance our technologies
to accelerate the pace of scientific discovery, enhance value for customers and fuel
growth for shareholders and employees alike. Visit www.thermofisher.com.

For further press information please contact: Laura Browne, The Scott Partnership, 1
Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44
1477 539539 Fax: +44 1477 539540 E-mail: thermouk@scottpr.com
###

Web Site: http://

Contact Details: The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel,
Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 E-mail:
thermouk@scottpr.com